

TUBERCULOSIS-III RESOURCE REPOSITORY

Department of Public Health, Tuberculosis Control Program

This repository is intended for licensed healthcare and other public health professionals working with Tuberculosis seeking quality patient care.

Advisory: for assistance with accessing any publications, please contact the [Tuberculosis Control Program](#) or the Department of [Public Health Library](#).



TB-III Resource Repository

1) Evaluation for and Diagnosis of TB Disease

I. CDC Guidelines

- Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017;64(2):e1-e33. doi:10.1093/cid/ciw694

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504475/>

II. Rapid Testing

- Gordin F, Slutkin G. The validity of acid-fast smears in the diagnosis of pulmonary tuberculosis. Arch Pathol Lab Med. 1990;114(10):1025-1027.
<https://pubmed.ncbi.nlm.nih.gov/1699506/>
- Mase SR, Ramsay A, Ng V, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2007;11(5):485-495.
<https://docserver.ingentaconnect.com/deliver/connect/iatid/10273719/v11n5/s3.pdf?expires=1644949093&id=0000&titleid=3764&checksum=3DE425992CA2B1DF77401E826A1F28A9>
- Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess. 2007;11(3):1-196.
doi:10.3310/hta11030
<https://njl-admin.nihr.ac.uk/document/download/2001457>
- Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005-1015. doi:10.1056/NEJMoa0907847
<https://www.nejm.org/doi/full/10.1056/nejmoa0907847>
- Barry P, Lin G (Curry International TB Center. "Experts on Xpert: A laboratorian and a clinician discuss interpretation of Xpert MTB/RIF results."
https://www.currytbcenter.ucsf.edu/sites/default/files/course-material/%5Bnid%5D/curry_center-xpert-09-2018-for_distribution.pdf
- National TB Controllers Association and Association of Public Health Laboratories. "Consensus statement on the use of Cepheid Xpert MTB/RIF assay in making decisions to discontinue airborne isolation in healthcare settings."
https://www.tbcontrollers.org/docs/resources/NTCA_APHL_GeneXpert_Consensus_Statement_Final.pdf
- Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep. 2009;58(1):7-10.
<https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm>
- Los Angeles County TB Control Program: "Guidelines for the use of *Mycobacterium tuberculosis* Nucleic Acid Amplification Tests (NAATs), Including Xpert MTB/RIF."
<http://ph.lacounty.gov/tb/docs/NAATs/NAATGuidelines09-15-2015f.pdf>
- Warshauer, APHL: "Nucleic Acid Amplification Testing for the Diagnosis of TB."

<https://www.aphl.org/conferences/proceedings/Documents/2008/TB-Conference/008-Warshauer.pdf>

III. Culture

- McWilliams T, Wells AU, Harrison AC, Lindstrom S, Cameron RJ, Foskin E. Induced sputum and bronchoscopy in the diagnosis of pulmonary tuberculosis. *Thorax*. 2002;57(12):1010-1014. doi:10.1136/thorax.57.12.1010
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1758793/>
- Ghodbane R, Raoult D, Drancourt M. Dramatic reduction of culture time of *Mycobacterium tuberculosis*. *Sci Rep*. 2014;4:4236. doi:10.1038/srep04236
<https://www.nature.com/articles/srep04236>
- Tyrrell FC, Budnick GE, Elliott T, et al. Probability of negative mycobacterium tuberculosis complex cultures based on time to detection of positive cultures: a multicenter evaluation of commercial-broth-based culture systems. *J Clin Microbiol*. 2012;50(10):3275-3282. doi:10.1128/JCM.01225-12
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457445/pdf/zjm3275.pdf>

IV. DST

- Chapter 3: Laboratory. In: Curry International TB Center and California Department of Public Health, *Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition*. 2016: 31-62.
<https://www.currytbcenter.ucsf.edu/products/drug-resistant-tuberculosis-survival-guide-clinicians-3rd-edition/chapter-3-laboratory>
- Lowenthal P, Lin SG, Desmond E, Shah N, Flood J, Barry PM. Evaluation of the Impact of a Sequencing Assay for Detection of Drug Resistance on the Clinical Management of Tuberculosis. *Clin Infect Dis*. 2019;69(4):668-675. doi:10.1093/cid/ciy937
<https://academic.oup.com/cid/article/69/4/668/5154873>
- “Dear Colleague Letter: Surveillance definitions for extensively drug-resistant (XDR) and pre-XDR tuberculosis” (January 18, 2022).
<https://www.cdc.gov/tb/publications/letters/2022/surv-def-xdr.html>

V. ATS Classification

- Diagnostic Standards and Classification of Tuberculosis in Adults and Children. *Am J Respir Crit Care Med*. 2000;161(4 Pt 1):1376-1395. doi:10.1164/ajrccm.161.4.16141
<https://www.atsjournals.org/doi/full/10.1164/ajrccm.161.4.16141>

VI. Infectiousness

- California Department of Public Health, California TB Controllers Association. “Guidelines for the Assessment of Tuberculosis Patient Infectiousness and Placement into High and Lower Risk Settings.”
<https://ctca.org/wp-content/uploads/2018/11/InfectiousnessOctober2017.pdf>
- LA County TB Control Program, “TB Manual Chapter Six: Contact Investigation” (Revised April 2020, version 1.1).
<http://ph.lacounty.gov/tb/docs/Chapter%206%20final%206.4.21.pdf>
- LA County TB Control Program, “Establishing an Infectious Period” worksheet.
<http://intranet.ph.lacounty.gov/ph/PDFs/TBControl/EstablishinganInfectiousPeriod.pdf>

2) Treatment of Drug-Susceptible Disease

I. CDC Guidelines

- Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195. doi:10.1093/cid/ciw376

<https://www.thoracic.org/statements/resources/tb-opi/treatment-of-drug-susceptible-tuberculosis.pdf>

II. Role of Individual Drugs

- Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis. 2000;4(9):796-806.

<https://www.ingentaconnect.com/content/iuatld/ijtld/2000/00000004/00000009/art00002;jsessionid=17b45d5jcbdkc.x-ic-live-01#>

III. Shorter Course Regimen (Study 31/HPZM)

- Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021;384(18):1705-1718. doi:10.1056/NEJMoa2033400

<https://www.nejm.org/doi/full/10.1056/NEJMoa2033400>

IV. eDOT

- CDC: "Implementing an Electronic Directly Observed Therapy (eDOT) Program"
- Garfein RS, Liu L, Cuevas-Mota J, et al. Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA. Emerg Infect Dis. 2018;24(10):1806-1815. doi:10.3201/eid2410.180459

https://wwwnc.cdc.gov/eid/article/24/10/18-0459_article

V. Dosing and Duration

- Tbcaculator.com:
- Hwang SK. "A Simple Mathematical Formula For Calculating The Necessary Duration of TB Treatment For a Given Regimen In A Patient Who Received Partial Treatment With A Different Regimen(s), Based on Proportional Credit." Presented at: 2015 NTCA Conference.

https://www.tbcontrollers.org/docs/conference/2015posters/Hwang_Simple_Formula_Treatment_Duration_Regimen_Change_2015NTC.pdf

3) Treatment of Drug-Resistant TB

I. CDC Guidelines

- Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;200(10):e93-e142. doi:10.1164/rccm.201909-1874ST

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857485/>

II. Pretomanid

- Pretomanid, FDA Printed Labeling.
- Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893-902. doi:10.1056/NEJMoa1901814

<https://www.nejm.org/doi/full/10.1056/NEJMoa1901814>

- “Provisional CDC Guidance for the Use of Pretomanid as part of a Regimen [Bedaquiline, Pretomanid, and Linezolid (BPAL)] to Treat Drug-Resistant Tuberculosis Disease.” Updated Feb 2, 2022.

<https://www.cdc.gov/tb/topic/drtb/bpal/default.htm>

4) Drug-Drug interactions

- I. Liverpool HIV Drug Interactions website
<https://www.hiv-druginteractions.org/checker>
- II. Lexicomp website
<https://online.lexi.com/lco/action/login>
Also available via UpToDate: <https://www.uptodate.com/drug-interactions/#di-druglist>
- III. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. *Curr Med Res Opin.* 2013;29(1):1-12. doi:10.1185/03007995.2012.747952
<https://www.tandfonline.com/doi/abs/10.1185/03007995.2012.747952?journalCode=icmo20>
- IV. Benedetti MS. Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs. *Pharmacol Res.* 1995;32(4):177-187. doi:10.1016/s1043-6618(05)80021-0. <https://pubmed.ncbi.nlm.nih.gov/8866833/>

5) Drug Intolerance/Allergies

- I. Chapter 9: Adverse Reactions. In: Curry International TB Center and California Department of Public Health, *Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Third Edition.* 2016: 246-276.
<https://www.currytbcenter.ucsf.edu/products/drug-resistant-tuberculosis-survival-guide-clinicians-3rd-edition/chapter-9-adverse>
- II. Curry International TB Center: “Nursing Guide for Managing Side Effects to Drug-resistant TB treatment.”
https://www.currytbcenter.ucsf.edu/sites/default/files/citc_nursingguide_english_v13_web_sp_reads.pdf
- III. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. *Am J Respir Crit Care Med.* 2006;174(8):935-952. doi:10.1164/rccm.200510-1666ST
<https://www.atsjournals.org/doi/pdf/10.1164/rccm.200510-1666ST>
- IV. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. *Am J Respir Crit Care Med.* 2003;167(11):1472-1477. doi:10.1164/rccm.200206-626OC
<https://www.atsjournals.org/doi/pdf/10.1164/rccm.200206-626OC>
- V. Lan Z, Ahmad N, Baghaei P, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. *Lancet Respir Med.* 2020;8(4):383-394. doi:10.1016/S2213-2600(20)30047-3.
<https://pubmed.ncbi.nlm.nih.gov/32192585/>

6) Therapeutic Drug Monitoring

- I. Peloquin C. The Role of Therapeutic Drug Monitoring in Mycobacterial Infections. *Microbiol Spectr.* 2017;5(1):10.1128/microbiolspec.TNMI7-0029-2016. doi:10.1128/microbiolspec.TNMI7-0029-2016. <https://journals.asm.org/doi/10.1128/microbiolspec.TNMI7-0029-2016>
- II. Ramachandran G, Chandrasekaran P, Gaikwad S, et al. Subtherapeutic Rifampicin Concentration Is Associated with Unfavorable Tuberculosis Treatment Outcomes. *Clin Infect Dis.* 2020;70(7):1463-1470. doi:10.1093/cid/ciz380.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931830/>

- III. Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2019;200(10):e93-e142. doi:10.1164/rccm.201909-1874ST.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857485/>
- IV. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. *Clin Infect Dis*. 2016;63(7):e147-e195. doi:10.1093/cid/ciw376.
https://www.cdc.gov/tb/publications/guidelines/pdf/clin-infect-dis.-2016-nahid-cid_ciw376.pdf

7) Treatment Failure and Post-Treatment Follow-up

- I. Seung KJ, Gelmanova IE, Peremitin GG, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. *Clin Infect Dis*. 2004;39(9):1321-1328. doi:10.1086/425005
<https://pubmed.ncbi.nlm.nih.gov/15494909/>
- II. Nunn AJ, Phillips PP, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. *Int J Tuberc Lung Dis*. 2010;14(2):241-242.
<https://www.ingentaconnect.com/content/iatld/ijtld/2010/00000014/00000002/art00019?crawler=true>
- III. Chapter 5: Treatment of Tuberculosis Disease. In: Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention. "Core Curriculum on Tuberculosis: What the Clinician Should Know, Seventh Edition." 2021:98-135.
https://apps.who.int/iris/bitstream/handle/10665/130918/9789241548809_eng.pdf

8) Special Topics

I. HIV/TB Co-infection

- NIH: Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV - Mycobacterium tuberculosis Infection and Disease
https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf
- Mfinanga SG, Kirenga BJ, Chanda DM, et al. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. *Lancet Infect Dis*. 2014;14(7):563-571. doi:10.1016/S1473-3099(14)70733-9
[https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(14\)70733-9/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(14)70733-9/fulltext)
- Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. *N Engl J Med*. 2010;362(8):697-706. doi:10.1056/NEJMoa0905848
<https://www.nejm.org/doi/full/10.1056/nejmoa0905848>
- Luetkemeyer AF, Kendall MA, Nyirenda M, et al. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. *J Acquir Immune Defic Syndr*. 2014;65(4):423-428. doi:10.1097/QAI.0000000000000030
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943693/>
- Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. *AIDS*. 2010;24(15):2381-2390. doi:10.1097/QAD.0b013e32833dfc68
<https://pubmed.ncbi.nlm.nih.gov/20808204/>

- Török ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis. 2011;52(11):1374-1383. doi:10.1093/cid/cir230
<https://pubmed.ncbi.nlm.nih.gov/21596680/>

II. Pregnancy

- Nguyen HT, Pandolfini C, Chiodini P, Bonati M. Tuberculosis care for pregnant women: a systematic review. BMC Infect Dis. 2014;14:617. doi:10.1186/s12879-014-0617-x
<https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-014-0617-x>
- Gould JM, Aronoff SC. Tuberculosis and Pregnancy-Maternal, Fetal, and Neonatal Considerations. Microbiol Spectr. 2016;4(6):10.1128/microbiolspec.TNMI7-0016-2016. doi:10.1128/microbiolspec.TNMI7-0016-2016
<https://journals.asm.org/doi/10.1128/microbiolspec.TNMI7-0016-2016>

III. Pediatrics

- Committee on Infectious Diseases, American Academy of Pediatrics, *Red Book 2021-2024, 32nd edition*.
<https://publications.aap.org/redbook>
- Graham SM, Cuevas LE, Jean-Philippe P, et al. Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An Update. Clin Infect Dis. 2015;61Suppl 3(Suppl 3):S179-S187. doi:10.1093/cid/civ581
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583568/>
- Heartland Center: "Pediatric TB Radiology for Clinicians."
https://www.heartlandntbc.org/wp-content/uploads/2021/12/pediatric_tb_radiology.pdf
- Cruz AT, Starke JR. Window Period Prophylaxis for Children Exposed to Tuberculosis, Houston, Texas, USA, 2007-2017. Emerg Infect Dis. 2019;25(3):523-528. doi:10.3201/eid2503.181596
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390765/>
- Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8(4):392-402.
<https://docserver.ingentaconnect.com/deliver/connect/iatid/10273719/v8n4/s2.pdf?expires=1644886802&id=0000&titleid=3764&checksum=77DD455A0F429CE0E787F9192CF6A26A>
- Lobato MN, Loeffler AM, Furst K, Cole B, Hopewell PC. Detection of Mycobacterium tuberculosis in gastric aspirates collected from children: hospitalization is not necessary. Pediatrics. 1998;102(4):E40. doi:10.1542/peds.102.4.e40
<https://publications.aap.org/pediatrics/article-abstract/102/4/e40/65563/Detection-of-Mycobacterium-tuberculosis-in-Gastric?redirectedFrom=fulltext>
- Cantwell MF, Shehab ZM, Costello AM, et al. Brief report: congenital tuberculosis. N Engl J Med. 1994;330(15):1051-1054. doi:10.1056/NEJM199404143301505
<https://www.nejm.org/doi/full/10.1056/NEJM199404143301505>
- Curtis AB, Ridzon R, Vogel R, et al. Extensive transmission of Mycobacterium tuberculosis from a child. N Engl J Med. 1999;341(20):1491-1495. doi:10.1056/NEJM199911113412002
<https://www.nejm.org/doi/full/10.1056/nejm199911113412002>

IV. CKD/ESRD/Dialysis

- British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee, Milburn H, Ashman N, et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax. 2010;65(6):557-570. doi:10.1136/thx.2009.133173
<https://thorax.bmj.com/content/thoraxjnl/65/6/559.full.pdf>
- Launay-Vacher V, Izzedine H, Deray G. Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clin Pharmacokinet. 2005;44(3):221-235. doi:10.2165/00003088-200544030-00001
<https://pubmed.ncbi.nlm.nih.gov/15762766/>

V. Cirrhosis/ESLD

- Kumar N, Kedarisetty CK, Kumar S, Khillan V, Sarin SK. Antitubercular therapy in patients with cirrhosis: challenges and options. World J Gastroenterol. 2014;20(19):5760-5772. doi:10.3748/wjg.v20.i19.5760
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024786/>

VI. Elderly

- Thomas TY, Rajagopalan S. Tuberculosis and aging: a global health problem. Clin Infect Dis. 2001;33(7):1034-1039. doi:10.1086/322671.
<https://academic.oup.com/cid/article/33/7/1034/429393>
- Caraux-Paz P, Diamantis S, de Wazières B, Gallien S. Tuberculosis in the Elderly. J Clin Med. 2021;10(24):5888. doi:10.3390/jcm10245888.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703289/>
- Gardner Toren K, Spitters C, Pecha M, Bhattarai S, Horne DJ, Narita M. Tuberculosis in Older Adults: Seattle and King County, Washington. Clin Infect Dis. 2020;70(6):1202-1207. doi:10.1093/cid/ciz306. <https://academic.oup.com/cid/article/70/6/1202/5448903>

VII. CNS TB

Diagnostics

- Pormohammad A, Nasiri MJ, McHugh TD, Riahi SM, Bahr NC. A Systematic Review and Meta-analysis of the Diagnostic Accuracy of Nucleic Acid Amplification Tests for Tuberculous Meningitis. J Clin Microbiol. 2019;57(6):e01113-18. doi:10.1128/JCM.01113-18.
<https://pubmed.ncbi.nlm.nih.gov/30944198/>
- Heemskerk AD, Donovan J, Thu DDA, et al. Improving the microbiological diagnosis of tuberculous meningitis: A prospective, international, multicentre comparison of conventional and modified Ziehl-Neelsen stain, GeneXpert, and culture of cerebrospinal fluid. J Infect. 2018;77(6):509-515. doi:10.1016/j.jinf.2018.09.003.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293313/>
- Thwaites GE, Chau TT, Farrar JJ. Improving the bacteriological diagnosis of tuberculous meningitis. J Clin Microbiol. 2004;42(1):378-379. doi:10.1128/JCM.42.1.378-379.2004.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC321694/pdf/0997.pdf>
- Xu HB, Jiang RH, Li L, Sha W, Xiao HP. Diagnostic value of adenosine deaminase in cerebrospinal fluid for tuberculous meningitis: a meta-analysis. Int J Tuberculosis Lung Dis. 2010;14(11):1382-1387.
<https://www.ingentaconnect.com/content/iuatld/ijtld/2010/00000014/00000011/art00005?crawler=true&mimetype=application/pdf>

Treatment

- Heemskerk AD, Bang ND, Mai NT, et al. Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis. *N Engl J Med*. 2016;374(2):124-134. doi:10.1056/NEJMoa1507062. <https://www.nejm.org/doi/pdf/10.1056/NEJMoa1507062?articleTools=true>
- Heemskerk AD, Nguyen MTH, Dang HTM, et al. Clinical Outcomes of Patients with Drug-Resistant Tuberculous Meningitis Treated with an Intensified Antituberculosis Regimen. *Clin Infect Dis*. 2017;65(1):20-28. doi:10.1093/cid/cix230. <https://academic.oup.com/cid/article/65/1/20/3796242>
- Svensson EM, Dian S, Te Brake L, et al. Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials. *Clin Infect Dis*. 2020;71(8):1817-1823. doi:10.1093/cid/ciz1071. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643733/>
- Cresswell FV, Meya DB, Kagimu E, et al. High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. *Clin Infect Dis*. 2021;73(5):876-884. doi:10.1093/cid/ciab162. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423465/>
- Marais S, Van Toorn R, Chow FC, et al. Management of intracranial tuberculous mass lesions: how long should we treat for?. *Wellcome Open Res*. 2019;4:158. doi:10.12688/wellcomeopenres.15501.2 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996525/>
- Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. *N Engl J Med*. 2004;351(17):1741-1751. doi:10.1056/NEJMoa040573. <https://www.nejm.org/doi/full/10.1056/nejmoa040573>

VIII. Pleural TB

- Gui X, Xiao H. Diagnosis of tuberculosis pleurisy with adenosine deaminase (ADA): a systematic review and meta-analysis. *Int J Clin Exp Med*. 2014;7(10):3126-3135. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238476/>
- Seibert AF, Haynes J Jr, Middleton R, Bass JB Jr. Tuberculous pleural effusion. Twenty-year experience. *Chest*. 1991;99(4):883-886. doi:10.1378/chest.99.4.883. <https://pubmed.ncbi.nlm.nih.gov/1901261/>

IX. Pericardial TB

- Wiysonge CS, Ntsekhe M, Thabane L, et al. Interventions for treating tuberculous pericarditis. *Cochrane Database Syst Rev*. 2017;9(9):CD000526. doi:10.1002/14651858.CD000526.pub2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618454/>
- Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and *Mycobacterium indicus pranii* in tuberculous pericarditis. *N Engl J Med*. 2014;371(12):1121-1130. doi:10.1056/NEJMoa1407380 <https://www.nejm.org/doi/full/10.1056/nejmoa1407380>

X. MSK TB

- MRC Working Party on Tuberculosis of the Spine, Darbyshire J. Five-year assessment of controlled trials of short-course chemotherapy regimens of 6-, 9- or 18-months' duration for spinal tuberculosis in patient's ambulatory from the start or undergoing radical surgery. Fourteenth report of the Medical Research Council Working Party on Tuberculosis of the Spine. *Int Orthop*. 1999;23(2):73-81. doi:10.1007/s002640050311

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619789/>

- Nene A, Bhojraj S. Results of nonsurgical treatment of thoracic spinal tuberculosis in adults. Spine J. 2005;5(1):79-84. doi:10.1016/j.spinee.2004.05.255
https://www.researchgate.net/publication/8078469_Results_of_nonsurgical_treatment_of_thoracic_spinal_tuberculosis_in_adults

XI. Ocular TB

- Albert DM, Raven ML. Ocular Tuberculosis. Microbiol Spectr. 2016;4(6): 10.1128/microbiolspec.TNMI7-0001-2016. doi:10.1128/microbiolspec.TNMI7-0001-2016
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5180603/pdf/nihms817027.pdf>
- Neuhouser AJ, Sallam A. Ocular Tuberculosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 31, 2021.
<https://www.ncbi.nlm.nih.gov/books/NBK559303/>

XII. Cutaneous TB

- Bravo FG, Gotuzzo E. Cutaneous tuberculosis. Clin Dermatol. 2007;25(2):173-180. doi:10.1016/j.clindermatol.2006.05.005 <https://pubmed.ncbi.nlm.nih.gov/17350496/>
- Hill MK, Sanders CV. Cutaneous Tuberculosis. Microbiol Spectr. 2017;5(1): 10.1128/microbiolspec.TNMI7-0010-2016. doi:10.1128/microbiolspec.TNMI7-0010-2016
<https://journals.asm.org/doi/10.1128/microbiolspec.TNMI7-0010-2016>
- Franco-Paredes C, Marcos LA, Henao-Martínez AF, et al. Cutaneous Mycobacterial Infections. Clin Microbiol Rev. 2018;32(1):e00069-18. doi:10.1128/CMR.00069-18.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302357/>

XIII. *Mycobacterium bovis*

- Dürr S, Müller B, Alonso S, et al. Differences in primary sites of infection between zoonotic and human tuberculosis: results from a worldwide systematic review. PLoS Negl Trop Dis. 2013;7(8):e2399. doi:10.1371/journal.pntd.0002399
<https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0002399>
- Hlavsa MC, Moonan PK, Cowan LS, et al. Human tuberculosis due to *Mycobacterium bovis* in the United States, 1995-2005. Clin Infect Dis. 2008;47(2):168-175. doi:10.1086/589240
<https://academic.oup.com/cid/article/47/2/168/356986>
- LoBue PA, Betacourt W, Peter C, Moser KS. Epidemiology of *Mycobacterium bovis* disease in San Diego County, 1994-2000. Int J Tuberc Lung Dis. 2003;7(2):180-185.
<https://www.ingentaconnect.com/content/iuatld/ijtld/2003/00000007/00000002/art00013?crawler=true>
- LoBue PA, Moser KS. Treatment of *Mycobacterium bovis* infected tuberculosis patients: San Diego County, California, United States, 1994-2003. Int J Tuberc Lung Dis. 2005;9(3):333-338.
<https://docserver.ingentaconnect.com/deliver/connect/iuatld/10273719/v9n3/s19.pdf?expires=1644887263&id=0000&titleid=3764&checksum=3A52288E9F6266E07DE993FCFCD394A2>
- Rodwell TC, Moore M, Moser KS, Brodine SK, Strathdee SA. Tuberculosis from *Mycobacterium bovis* in binational communities, United States. Emerg Infect Dis. 2008;14(6):909-916. doi:10.3201/eid1406.071485.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600278/>